Literature DB >> 9121366

Muscarinic agonists in Alzheimer's disease.

J H Growdon1.   

Abstract

As therapeutic agents, M1 agonists in the short-term may palliate symptoms of AD and improve memory function. In the long-term, M1 agonists have the potential to modify the underlying pathophysiology of AD, and thereby prevent or retard the course of dementia.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9121366     DOI： 10.1016/s0024-3205(97)00039-8

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  5 in total

1.  Muscarinic stimulation of synaptic activity by protein kinase C is inhibited by adenosine in cultured hippocampal neurons.

Authors:  A Bouron; H Reuter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors.

Authors:  X P Huang; P I Nagy; F E Williams; S M Peseckis; W S Messer
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  Pharmacological discrimination between muscarinic receptor signal transduction cascades with bethanechol chloride.

Authors:  Liwang Liu; Ann R Rittenhouse
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

4.  Arachidonic acid mediates muscarinic inhibition and enhancement of N-type Ca2+ current in sympathetic neurons.

Authors:  Liwang Liu; Ann R Rittenhouse
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-20       Impact factor: 11.205

5.  The effect of scopolamine in older rabbits tested in the 750 ms delay eyeblink classical conditioning procedure.

Authors:  Diana S Woodruff-Pak; John T Green; Jonathan T Pak; Boris Heifets; Michelle H Pak
Journal:  Integr Physiol Behav Sci       Date:  2002 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.